Search Results

You are looking at 61 - 70 of 967 items for :

  • "NCCN Clinical Practice Guidelines in Oncology NCCN Guidelines" x
  • Refine by Access: Content accessible to Me x
Clear All
Full access

David S. Ettinger, Michael Kuettel, Jennifer Malin, Joan S. McClure, Mary Lou Smith, Andrew D. Zelenetz, and F. Marc Stewart

Clinical Practice Guidelines in Oncology (NCCN Guidelines) from some of the members who were in the delivery room when they were born. For example, in 1996, the NCCN Guidelines for Lung Cancer were created by a 7-member lung cancer panel and included 40

Full access

Ali Bazarbachi and Andrew D. Zelenetz

East and North Africa) region guideline committees began the process of modifying the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for several tumor types, including lymphoma. The MENA region includes Morocco, Algeria, Tunisia

Full access

Robert W. Carlson, D. Craig Allred, Benjamin O. Anderson, Harold J. Burstein, W. Bradford Carter, Stephen B. Edge, John K. Erban, William B. Farrar, Andres Forero, Sharon Hermes Giordano, Lori J. Goldstein, William J. Gradishar, Daniel F. Hayes, Clifford A. Hudis, Britt-Marie Ljung, P. Kelly Marcom, Ingrid A. Mayer, Beryl McCormick, Lori J. Pierce, Elizabeth C. Reed, Mary Lou Smith, George Somlo, Neal S. Topham, John H. Ward, Eric P. Winer, and Antonio C. Wolff

Overview T he NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Breast Cancer: Noninvasive and Special Situations presented here are the work of the NCCN Breast Cancer panel members. Categories of evidence and consensus were

Full access

Robert W. Carlson

The uses and distribution of the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) continue to increase dramatically, with more than 3 million downloads from the NCCN Web site in 2010 alone. More than 230,000 individuals in 194

Full access

and includes a variety of regimen choices. The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) endorse a number of anthracycline- and non-anthracycline–based options. Data in this figure are adapted from distribution data provided by

Full access

Mark Lazenby

Background Moving new health care discoveries and innovations from evidence into everyday clinical practice remains a challenge, despite demonstrated benefits. 1 The evidence-based NCCN Clinical Practice Guidelines in Oncology (NCCN

Full access

Omar Shamieh and Abdul-Rahman Jazieh

A n initiative was launched to adapt several of the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) to the Middle East and North Africa (MENA) region. Palliative care was one area of cancer treatment selected because of its high

Full access

Robert J. Morgan, Ronald D. Alvarez, Deborah K. Armstrong, Robert A. Burger, Mariana Castells, Lee-may Chen, Larry Copeland, Marta Ann Crispens, David Gershenson, Heidi Gray, Ardeshir Hakam, Laura J. Havrilesky, Carolyn Johnston, Shashikant Lele, Lainie Martin, Ursula A. Matulonis, David M. O’Malley, Richard T. Penson, Steven W. Remmenga, Paul Sabbatini, Joseph T. Santoso, Russell J. Schilder, Julian Schink, Nelson Teng, Theresa L. Werner, Miranda Hughes, and Mary A. Dwyer

especially encouraged. Overview The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Ovarian Cancer discuss management of epithelial ovarian cancer, which is the most common type of ovarian cancer. The guidelines also discuss

Full access

Pancreatic Adenocarcinoma, Version 2.2012

Featured Updates to the NCCN Guidelines

Margaret A. Tempero, J. Pablo Arnoletti, Stephen W. Behrman, Edgar Ben-Josef, Al B. Benson III, Ephraim S. Casper, Steven J. Cohen, Brian Czito, Joshua D. I. Ellenhorn, William G. Hawkins, Joseph Herman, John P. Hoffman, Andrew Ko, Srinadh Komanduri, Albert Koong, Wen Wee Ma, Mokenge P. Malafa, Nipun B. Merchant, Sean J. Mulvihill, Peter Muscarella II, Eric K. Nakakura, Jorge Obando, Martha B. Pitman, Aaron R. Sasson, Anitra Tally, Sarah P. Thayer, Samuel Whiting, Robert A. Wolff, Brian M. Wolpin, Deborah A. Freedman-Cass, and Dorothy A. Shead

the 2012 version of the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Pancreatic Adenocarcinoma, the combination of a fluoropyrimidine (5-FU/leucovorin or capecitabine) with oxaliplatin was added as a possible first-line treatment

Full access

Apar Kishor P. Ganti, Billy W. Loo Jr., Michael Bassetti, Collin Blakely, Anne Chiang, Thomas A. D'Amico, Christopher D'Avella, Afshin Dowlati, Robert J. Downey, Martin Edelman, Charles Florsheim, Kathryn A. Gold, Jonathan W. Goldman, John C. Grecula, Christine Hann, Wade Iams, Puneeth Iyengar, Karen Kelly, Maya Khalil, Marianna Koczywas, Robert E. Merritt, Nisha Mohindra, Julian Molina, Cesar Moran, Saraswati Pokharel, Sonam Puri, Angel Qin, Chad Rusthoven, Jacob Sands, Rafael Santana-Davila, Michael Shafique, Saiama N. Waqar, Kristina M. Gregory, and Miranda Hughes

described in the complete version of the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Small Cell Lung Cancer (available at NCCN.org ). This shorter selection for JNCCN has been condensed to focus on metastatic (known as extensive